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Plans for guideline revision
The proposed revision for this set of recommendations is scheduled for 2021.
Background
Inherited EB is a group of rare genetic disorders characterized by skin fragility and mechanically induced blistering. EB comprises four main types -EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler syndrome (KS), with more than 30 clinical subtypes (Table 2) . EB is clinically heterogeneous, including a broad spectrum of severity. At one end of the spectrum, severe congenital cutaneous and mucosal fragility may be accompanied by extracutaneous involvement and complications, often resulting in a limited life span. In contrast, mild skin fragility may be localised to extremities, begin later in life, or only manifest as nail dystrophy. 3 In children and adults, clinical features may be typical and allow the clinical diagnosis of the EB type and subtype. 4 In neonates and in individuals with mild clinical manifestations the determination of the EB type and subtype relies on laboratory diagnosis. In some situations, particularly in families with a first case of EB and apparent de novo occurrence, discrimination between autosomal dominant (AD) and recessive (AR) inheritance is not possible without genetic testing.
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Classification of EB with genes and causative variants
Classification of EB into four main types is based on the ultrastructural level of skin cleavage. 6 In EBS splitting occurs within the epidermis (intraepidermal), in JEB within the lamina lucida (junctional), in DEB below the basement membrane within the
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superficial dermis (dermal) and in the KS there is a mixed level of skin blistering (Table 2 ). An EB classification scheme (onion-skin) has been developed which sequentially takes into account the level of skin cleavage corresponding to the major EB type, the clinical severity, the inheritance pattern, and the molecular defect, including the relative protein expression and the disease-causing sequence variant(s). 6 A detailed description of this EB classification system and the clinical subtypes has been reported by Fine et al. 6 Clinical features of EB
Cutaneous and mucosal involvement in EB
Skin blistering on sites of mechanical trauma is the main clinical feature of EB. Depending on the level of skin cleavage, blisters may be superficial as with EBS and result in erosions, or more profound such as with JEB, DEB and KS and lead to ulcerations.
Blisters may be generalised, disseminated to different body sites, or localised to the extremities. Skin defects heal spontaneously by restitutio ad integrum, or with residual hypo-/hyper-pigmentation, skin atrophy or scarring. Recurrent and chronic skin defects may result from permanent exposure of the fragile skin to mechanical trauma.
Oral, oesophageal, tracheal, genitourinary, and ocular mucosal membranes may be affected by erosions, ulcerations and scarring. Fragility of the cutaneous adnexa may involve nails which may become dystrophic or lost, and hair, leading to alopecia.
These features are characteristic to specific EB subtypes. 6 Progressive scarring results in contractures and/or mutilations of the extremities, microstomia, disfigurement and oesophageal stenosis, which are common in KS and in DEB, or dyspnoea with risk of suffocation in specific forms of JEB.
Teeth may be affected because of amelogenesis imperfecta (JEB) or secondarily to the fragility and scarring of the oral mucosa leading to impaired oral hygiene (DEB).
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Extracutaneous involvement in EB
Due to the high caloric consumption and acquired complications in the context of permanent skin damage and regeneration, EB subtypes with generalised severe blistering are characterized by secondary involvement of other organs or systems. 7, 8 This is mainly the case with generalized recessive DEB (RDEB), which may be accompanied by failure to thrive, anaemia, osteoporosis, joint contractures, cardiomyopathy, renal amyloidosis, etc. 8 In syndromic EB types, expression of the affected genes in extracutaneous tissues leads to primary involvement of other organs or systems. 9 Examples are: muscular dystrophy in EBS with plectin deficiency; pyloric atresia in EBS with plectin deficiency and in JEB with integrin α6β4 deficiency; cardiomyopathy in EBS caused by KLHL24 or PLEC sequence variants and in skin fragility syndromes with DSP and JUP sequence variants; 10 lung fibrosis and nephrotic syndrome in JEB with deficiency of the integrin α3 subunit, 11 connective tissue abnormality in patients with PLOD3 gene mutation, 12 or nephrotic syndrome in patients with CD151 deficiency. 13 For detailed descriptions of the clinical features of EB, original and review articles are available. [6] [7] [8] 14, 15 
Molecular basis of EB
In EB, mucocutaneous fragility results from decreased resilience of the structures which confer mechanical stability to the epidermis (keratin cytoskeleton, desmosomes) and to the cutaneous basement membrane zone (BMZ) (hemidesmosomes, focal adhesions, anchoring filaments and anchoring fibrils) ( Figure 1 ). These multimolecular suprastructures link the keratinocytes to each other, the basal keratinocytes to the underlying basement membrane, and the basement membrane to the underlying connective tissue. Disease-causing variants in at least 21 different genes account for the genetic and allelic heterogeneity of EB (Table 2 ). These genes encode proteins which mainly play structural roles; their major characteristics, expression pattern and functions are summarized in the Supplementary Table 1 .
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Laboratory diagnosis of epidermolysis bullosa
Types of laboratory referral
This guideline provides the steps in making an accurate diagnosis in case of clinical suspicion of EB. It is therefore recommended that laboratories consider the testing criteria formulated and agreed by these guidelines. However, there are vast variations and differences among EB clinical and diagnostic centres around the world with respect to the diagnostic equipment and methods available, and also between the national health system regulations governing rare disease care and genetic testing, and reimbursement for these services. Therefore, one single guideline at this stage may not be able to cover all aspects related to laboratory diagnosis of EB. Such situation(s) may require EB clinicians and diagnostic scientists to make a reasonable adjustment, provided that such adjustment does not deviate from this guideline significantly.
Neonate with skin fragility A newborn baby showing congenital absence of skin, blistering or skin fragility should be referred to an EB diagnostic centre for diagnosis as soon as possible. In addition to a blood sample for the extraction of genomic DNA, a skin biopsy should be taken from the patient. The confirmation of diagnosis can be achieved (i) by using the skin biopsy for immunohistochemistry (IHC) with fluorescence labelled secondary antibodies (immunofluorescence mapping (IFM)); or (ii) by skin ultrastructure examination by transmission electron microscopy (TEM); or (iii) by direct genetic testing, which is dependent on the facility and resource availability in the diagnosis centre. In some cases, all three approaches are necessary. Although genetic testing can make a definite diagnosis and its turnaround time is progressively shortening, IFM can provide the diagnosis within hours, thus ensuring appropriate neonate management. While this will undoubtedly change in the coming years, IFM still remains the first method of choice.
16
Paediatric and adult patient with skin fragility As the presentation of clinical manifestations may become clearer with a patient's age, any paediatric and/or adult patient with skin fragility w h o has already developed typical manifestations of the EB subtype can be referred directly to a diagnostic centre for genetic testing. Dependent on situation the method chosen can be next generation sequencing (NGS) or Sanger sequencing (SS). If both methods fail to provide diagnosis, IFM and EM may help to understand the molecular and ultrastructural basis of skin fragility. The details of this part will be discussed later in this guideline.
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Prenatal diagnosis
When the carrier status of the familial sequence variant has been determined in both parties of an expecting couple, a DNA based prenatal testing can be offered to the couple upon their request. S o m e c o u n t r i e s m a y h a v e t h e i r s p e c i f i c l o c a l r e g u l a t i o n a n d e t h i c a l r e q u i r e m e n t s w h i c h n e e d t o b e c o n s i d e r e d b e f o r e a P N D c a n t a k e p l a c e . According to the national regulations, the test can be referred by a genetics counsellor (preferably with knowledge of EB) or a dermatologist specialised in EB. Referral for prenatal testing by linkage analysis would need to be discussed in detail with professionals in a genetic diagnostic centre; as such situation usually requires substantial tests and knowledge of the index case.
EB laboratory diagnostic flow chart
In cases with skin fragility and blistering, standard histopathological evaluation and 
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If clinical features and family history are suggestive of EB, laboratory diagnosis is always indicated, after informed consent is given by the patient, parents or the caregivers (as shown in Figure 2 ). Ideally, both genetic testing and IFM should be performed to allow complete molecular characterisation of EB, both at the DNA and protein level. These methods provide complementary information that enables prediction of the consequences of novel sequence variants and genotype-phenotype correlations. However, the benefit for people with EB and their families, the availability of different methods, the national regulations and economic factors must be considered when EB laboratory diagnosis is planned. Prioritisation of strategies can shorten the time to diagnosis and save resources but requires expertise of the clinicians and of the diagnostic scientists (Table 3 ). In a clinical diagnostic setting, the following main prioritisation strategies of EB laboratory diagnosis can be considered:
• In neonates, IFM should be the first diagnostic step since it delivers rapid results.
In parallel, genetic testing should always be performed.
• In cases with characteristic clinical features, including localised dominant EBS or DEB for which IFM will frequently not deliver a useful result, genetic testing by NGS or SS can deliver a final diagnosis.
• In EB (sub) types with genetic heterogeneity or in cases with uncharacteristic findings, without clear candidate gene, genetic testing by NGS is recommended. If pathogenic variants are detected in the index case, the parents should be tested to determine the pattern of inheritance. Other family members can be tested to confirm segregation and allow genetic counselling.
If no pathogenic variant(s) are detected in the index case, the diagnostic algorithm must be adapted as described below.
Genetic testing for EB
The p a t h o g e n i c sequence variants will provide clarity for the definitive diagnosis, prognosis, and inheritance for the patient with EB and his/her family, and is therefore essential. Moreover, it is the basis for the risk calculation of having an affected offspring in the same generation by the same biological parents of the proband or his/her offspring
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NGS targeted gene panel and whole exome sequencing in EB (Level of evidence 2++, grade of recommendation B)
The term NGS describes the techniques used to analyse several genes and a large number of DNA samples in parallel using high-throughput technology. NGS can be applied to only sequence defined DNA targets (e.g. targeted gene panels) or to sequence entire exomes (WES), genomes (whole genome sequencing, WGS) or transcriptomes (RNA-Seq), followed by post-test filtering. Recently, NGS has been proved to be one of the most important tools for accurately and comprehensively identifying pathogenic variants in EB.
3 , 1 9 -2 4
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Supplementary Table 2 summarizes the pros and cons of different genetic testing approaches. NGS platforms and subsequent data reporting are recommended to be in accordance with the guidelines published by the European Society of Human Genetics, 25 as well as by Human Genome Variation Society (HGVS). 26, 27 In EB (sub) types with genetic heterogeneity, in cases without a clear candidate gene, or where candidate genes have been ruled out, or in cases when SS was the first chosen method and did not i d e n t i f y the pathogenic variant, targeted NGS with the 21 known EB genes or WES with targeted filtering for EB genes is recommended (level of evidence 2++, grade of recommendation B). [19] [20] [21] [22] [23] [24] 28 Subsequently, confirmation of novel pathogenic variants found this way should be performed b y SS (level of evidence 4, grade of recommendation D). Recent data showed that in clinically unaffected parents, mosaicism may be detected by NGS more often than expected (depending of the coverage of the NGS platform), which has important impact on genetic counselling. 29 The advantage of targeted EB gene panels is that it obviously has a much higher coverage per gene and base. However, current WES platforms should also provide sufficient coverage per gene and base to provide accurate results, but it is recommended to confirm this in individual laboratories. The regions where coverage is not reaching recommended values (at least 95% of bases more than 20x) should be analysed separately by SS. Finally, the power of WES in finding new genes as well as multi-genes mutations in EB patients has been demonstrated.
12,19,30-33
Sanger sequencing
(Level of evidence 2++, grade of recommendation B)
Direct bidirectional SS has been the first diagnostic method for identifying the pathogenic variants in EB. All over the world, similar Sanger-based protocols have been successful for disclosing causative pathogenic sequence variants in EB genes. 11, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Polymerase chain reaction (PCR) products (300-600 base pairs in size)
are generated by using gene-specific primer pairs (sequences have been published for EB genes) covering the coding region and the exon-intron boundaries. Subsequently these are examined by SS.
Direct SS is a rapid and cost-and time-effective method for: (i) genetic testing of small known candidates genes, (ii) carrier identification when the family's pathogenic variant is known, (iii) prevalent founder/ethnic pathogenic variant screening with
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Once a sequence variant is detected, it needs to be thoroughly evaluated in order to conclude its pathogenicity. It is recommended to classify all variants according to guidelines published by the ACMG. 45 In 2015, ACMG elaborated standards and guidelines for the interpretation of sequence variants, which provide a step-by-step procedure for consistent variant classification (Supplementary Table 3 
To prevent confusion a b o u t i n h e r i t a n c e pattern definition, i n p a r t i c u l a r w h e n t h e p a t i e n t i s t h e f i r s t a f f e c t e d i n the family, it is recommended to test both parents for carrier status. 
Limitation and uncertainty
One of the major disadvantages of SS is that the pre-selection of a candidate gene is mandatory ( 
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This article is protected by copyright. All rights reserved. Especially with the unbi ased, h ypothes is-f ree WES, WGS and RNA-Seq, the major challenge will be the interpretation of all available data or 'how to locate the needle in the hay-stick' (noise). This requires robust and reliable data analysis pipelines that are commercially available or can be built in-house. The latter approach necessitates a dedicated bioinformatics division, which at present is not available to most diagnostic service labs. However, with the ongoing progression of DNA-diagnostics and generation of terabytes of data per patient, it is predicted that bioinformatics will become an increasingly important specialty for the diagnostics of the very rare molecularly unsolved patients with EB. Taken together, such analyses will mostly be done in a research setting; international collaboration in these cases is recommended (level of evidence 4, grade of recommendation D).
Immunofluorescence mapping (Level of evidence 2+, grade of recommendation C)
Immunofluorescence mapping (IFM, also called antigen mapping) on frozen sections is a rapid technique for EB subtype diagnosis w h i c h is also feasible in resource-limited settings. 62 Variations of this technique include using different panels of antibodies or different IHC detection methods. [62] [63] [64] [65] IHC on frozen sections, is possible, 62 but requires nearly the same equipment as IFM excluding the need of a fluorescence microscope. In formalin-fixed, paraffin-embedded samples antigen loss is a major problem for most
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molecules of interest for EB diagnosis, and it is therefore not recommended.
Nevertheless, a high sensitivity and specificity can be reached at very low costs using two antibodies (anti-keratin 14, and anti-type IV collagen) on paraffin embedded sections. 65 H&E staining may be useful in resource-limited situations.
66
Biopsy samples
For the diagnosis of EB by IFM, a 4 to 6 mm punch or shave cutaneous biopsy sample is necessary. In general, it is recommended to take the biopsy from an area of the body which is not exposed to the sun (i.e. inner part of the upper arm), as skin exposed to the sun may create non-specific background fluorescence, thus interfering with the interpretation. Application of a topical anaesthetic cream before taking the biopsy may induce artificial skin cleavage. 67, 68 The biopsy should include perilesional (clinically normal appearing) skin as well as a small part of a fresh blister (less than 12 hours) (Supplementary Figure 1a) . If no fresh blister is present, a new blister can be induced by rubbing the patient skin adjacent to a lesional area until it becomes red or blistered. [69] [70] [71] [72] An alternative method to induce a new blister after taking the biopsy is by suctioning the epidermal side of the biopsy with a 20-ml-syringe until a macroscopic blister appears. 73 However, the quality and reliability of this technique has not b e e n validated in a d d i t i o n a l p u b l i c a t i o n s . Usually the skin of EB patients is extremely fragile and the trauma of the biopsy may by itself lead to dermo-epidermal separation.
Handling of biopsy samples
The biopsy sample for IFM can be either snap frozen in liquid nitrogen, or placed in Michel's medium 74, 75 (Supplementary Table 5 ) and stored at room temperature until use or shipment. The samples stored in this medium can be sent worldwide to any specialised laboratory. 76 It is though advisable to ship them as soon as possible to the reference laboratory as signs of epidermal cell cytolysis have been observed after just 48
hours. Samples which are frozen in Michel's medium are deemed unusable for analysis purposes. Alternatively, samples can be shipped frozen in dry ice. Shipment in sterile saline, in Dulbecco's Modified Eagle Medium or in RPMI-1640 medium is also possible (with arrival to the EB diagnosis centre within 1-3 days, since artificial junctional cleavage and other artefacts may occur).
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Results and interpretation
IFM allows for the visualisation of the cleavage level in the blister of the patient's skin relative to the protein markers used. The presence of a detectable and consistent cleavage plane within the skin allows the diagnosis of the major EB type ( Table 2 , Supplementary Figure 1c) . Briefly, type IV collagen can be used as a marker to delineate the plane of cleavage, as it is never affected in EB. Staining of type IV collagen to the floor of the blister is indicative of a junctional or an intraepidermal blister, whereas staining to the roof defines a dermal blister. In EBS, the cleavage occurs in the epidermis, either within the basal cell layer or above. An irregular keratin 14 labelling surrounding unstained areas is indicative of (micro) blistering within the basal cell layer. In KS, the plane of cleavage is variable. It can be intraepidermal, junctional or dermal, or can occur at multiple levels in the same specimen. Broad reticulated staining of type IV collagen, laminin-332 and type VII collagen can be seen in KS.
The IFM staining result of NHS is compared to the IFM pattern and staining intensity of the patient´s skin. This permits assessment of the presence, absence or reduced/altered expression of different proteins analysed in the skin of the patient. Sensitivity and specificity of IFM has been compared to TEM 77, 78 or evaluated in relation to clinical diagnosis in a few case series of patients with all types of suspected EB. 62, 73, 79 Only in two of these studies the internal reference standard was genetic diagnosis. 62, 77 Of note, the only prospective study, which used genetic testing as an independent standard criterion to measure the diagnostic accuracy of each test, reported that IFM is more sensitive and specific than TEM, though the difference did not reach statistical significance due to insufficient number of samples evaluated. 77 If genetic testing identifies VUS, or no pathogenic variants in EB associated genes are found, alterations in the immunostaining pattern and intensity may provide valuable information on the affected protein. 80, 81 Moreover, in such situations, obtaining keratinocytes and/or fibroblasts from a patient's skin sample enables expression and functional studies.
Limitations and uncertainty
There 
Electron microscopy (Quality of evidence 2+, grade of recommendation C)
Electron microscopy led to the initial classification of EB into three major typessimplex, junctional and dystrophic -based on the precise level of tissue separation.
82-84
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Method
When a biopsy for TEM is planned, the criteria for the choice of the skin biopsy site and the method used to acquire it, are the same as described for IFM. 85 The skin sample should be immediately immersed in an appropriate fixative for TEM, which usually contains both glutaraldehyde and formaldehyde (e.g. Karnovsky's fixative) and is suitable for sample shipment. Subsequent processing for TEM examination comprises cutting the sample into small pieces (0.5 to 1 mm thick), followed by further fixation, post-fixation in osmium tetroxide, dehydration, epoxy resin embedding, and semithin section preparation according to standard TEM methods. Light microscopy examination of semithin sections will permit the selection of both fields containing blistering areas and intact skin for ultrathin sections preparation and examination.
Results and interpretation
TEM examination allows the definition of the blister level within the skin to be defined as detailed in Table 2 . Interpretation of TEM analysis requires a deep knowledge of epithelial cell-cell and cell-matrix adhesion structures and their appearance in normal and EB skin.
Under skin ultrastructure, the cleavage occurs: (i) within the epidermis in EBS, (ii) at the level of the lamina lucida of the cutaneous BMZ in JEB, (iii) below the lamina densa of the BMZ in DEB, and (iv) at multiple levels in KS. 6 Overall the most common EBS subtypes are due to sequence variants in the keratin 5 and 14 genes, where the cleavage is within the cytoplasm of the epidermal basal cells, usually beneath the nucleus. 85 Additional specific findings in these EBS subtypes include: (i) aggregation and clumping of keratin tonofilaments within the basal keratinocytes, regularly detected in both lesional and perilesional skin in EBS generalised severe 86 and in some cases of EBS with mottled pigmentation, 87 and (ii) lack of keratin tonofilaments in basal keratinocytes in recessive EBS due to KRT14 sequence variants. 88, 89 The ultrastructural characteristics of rare EBS subtypes are described in Table 2 .
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This article is protected by copyright. All rights reserved. RDEB generalised severe shows rudimentary or absent anchoring fibrils, in addition to subepidermal blistering. 85, 101 Variably hypoplastic anchoring fibrils are usually observed also in the other RDEB, and in dominant DEB subtypes. Finally, bullous dermolysis of the newborn is characterised by the presence of pathognomonic membrane-bound inclusions containing amorphous material and rod-like structures, named stellate bodies, in basal keratinocytes.
102-104
The cleavage plane in KS may vary, being located either within the epidermis or the lamina lucida or beneath the lamina densa, with multiple separation levels frequently visible in the same specimen. Other characteristic findings include extensive reduplications of the lamina densa. 105 As discussed earlier regarding the limitation of IFM and TEM, when neither blistering nor any typical finding can be detected by both IFM and TEM examination, genetic testing should be performed. TEM is at present still an important method for the early diagnosis of a limited number of EB subtypes, in particular EBS generalised severe, autosomal recessive EBS caused by EXPH5 or DST1e, and, possibly, bullous dermolysis of the newborn. In these subtypes, IFM may not be able to provide clear result. Thus, the early detection of specific ultrastructural features has direct prognostic and management implications.
In cases in which VUS or no clear pathogenic variants are identified by genetic testing, TEM may provide valuable information on the underlying ultrastructural anomalies.
59
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Limitations and uncertainty
TEM is a more expensive, labour-intensive and time-consuming method than IFM. It requires both highly skilled technical work for specimen processing and preparation, and specific expertise for their observation and interpretation, thus resulting in TEM for EB diagnosis being performed in a limited number of centres. In addition, in several EB subtypes there are no specific ultrastructural findings and TEM does not allow direct identification and quantification of the defective protein. When blistering or adhesion structure abnormalities are not present or detectable in a TEM specimen such as with localised EBS or very mild DEB subtypes, TEM findings can be inconclusive.
Finally, the determination of subtle abnormalities of epithelial adhesion structures can require morphometric analysis which is not feasible in a routine diagnostic setting.
Reporting scenarios
When issuing the report, it should include as much patient information as possible, as it is often the case that the EB patient is under the care of different medical professionals in diverse locations or facilities. The reason for referral should be restated, which at least specifies the type of test that was requested, e.g. diagnostic,
carrier, or prenatal test. Reference to the laboratory tests carried out must include brief mention of the method(s) used and details of what was tested. According to the settings in different EB diagnostic centres, the report can be issued by a laboratory scientist or consultant dermatologist, or sometimes by both. The report should only be send to the referral physician, and the responsibility of the staff involved in the reporting should be clearly indicated.
Report for genetic testing
• a) Genetic testing in an affected individual (index case) The genetic testing report must provide a full and clear interpretation of the results, as the report may be read by a variety of professionals involved in the care of the patient, many of whom may n o t be familiar with genotyping results. It is also recommended to use HGVS nomenclature. For point sequence variants, the sequence change should be stated at the DNA level (assuming it has been characterized in DNA), and as predicted in the protein. Also for clarity it is useful to state in words what the change is, and its predicted effect. In addition, the paternal/maternal origin of the sequence variant, or its de novo occurrence should be specified. In all mutation reports, it is
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essential to quote the accession number of the gene reference sequence which has been used in classifying the mutation. When reporting a deletion or duplication, the report must clearly convey whether the end points of a deletion or duplication have been determined (this is not always possible in a routine diagnostic setting). The report should always mention that genetic consultation is recommended or legally obligated in most countries, and that screening for relatives is possible. Whenever appropriate carrier risk and risk for having affected offspring should be calculated. 106 
This article is protected by copyright. All rights reserved. Prenatal diagnostic (PND) report The implication of the pathogenic variant present or absent in the PND must be clearly stated and whether the foetus is clinically affected or unaffected must also be clearly stated. According to the local regulation, i t should be stated if the foetus is a carrier or not. The test results for maternal contamination also need to be clearly stated to further confirm the validity of the result. According to local regulation, the sex of the foetus can be indicated in the report if the person who requests the report feels such information might be of interest.
In addition to the aforementioned details of a report, when NGS analysis has been performed, the report must also include a list of genes tested within a particular panel.
All variants reported need to be annotated according to HGVS nomenclature. The transcript being used for providing c. and p. nomenclature and exon numbering should be provided in the report.
Report for IFM
The report for IFM should include a list of the primary antibodies used, the expected staining pattern and the strength of signal observed in normal control skin for each antibody, compared with the staining pattern and signal strength in patient skin.
A clear conclusion should be made from these observations when the result is conclusive. However, IFM may sometimes lead to an unclear or inconclusive result such as 'no significant difference has been observed between normal control skin and patient skin, and no blister formation'. In these cases, the report should suggest the possibility of further tests, or a differential diagnosis.
Report for TEM
The report for TEM is usually done only with patient skin. This should include a semithin section finding description. The report of ultrastructural findings should concern the entire epidermis, from the horny layer to basal keratinocytes, and all the structural components of the cutaneous BMZ, from the hemidesmosomes with tonofilament attachment to anchoring filaments and anchoring fibrils. The conclusion should include whether the patient is affected with EB, which type and, if defined, which subtype, and what would be the next test in order to reach a final confirmation. Alternatively, the report should specify that the results are not conclusive and further test to be performed.
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Recommendations for EB laboratory diagnosis
How does the guideline work in practice
As this guideline is intended for international use, it is not possible to formulate a strategy for its implementation in all clinical centres. However, the activities of DEBRA International will aid in the dissemination of the guidelines and facilitate adoption by the proposed user groups. These guidelines will be translated into other languages and a patient version will be made to aid accessibility. DEBRA International would value feedback on the guideline so they can continue to improve its quality and impact.
Two examples of how to use the guideline in practice are given below. 
Case 1
Type of referral: At disease onset, at birth
Clinical information: Female newborn with congenital skin defects on upper and lower limbs, mechanically induced skin blisters and milia. Family history was negative, parents were not related.
IFM:
A skin biopsy was performed on the second day of life and analysed by IFM with an extended panel of 18 antibodies to proteins of the BMZ. 64 Result: no skin cleavage, all markers stained comparable to the normal skin. TEM was not available.
Genetic testing:
Genetic testing was performed with a targeted EB gene panel. 
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Suspected dominant DEB due to a de novo pathogenic variant was discarded.
Causative pathogenic variants support IFM results and clinical manifestation. The partner was also tested, and no pathogenic variant was disclosed. Genetic counselling was provided. 
Figures
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Tables
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Legend: *, DNA based prenatal diagnosis is only possible when familial mutation is known
